Nj State Employees Deferred Compensation Plan adds Alexion Pharmaceuticals (ALXN) to its portfolio

Alexion Pharmaceuticals (ALXN) : Nj State Employees Deferred Compensation Plan added new position in Alexion Pharmaceuticals during the most recent quarter end. The investment management firm now holds 7,000 shares of Alexion Pharmaceuticals which is valued at $963,620 , the company said in a statement filed on Aug 3, 2016 with the SEC.Alexion Pharmaceuticals makes up approximately 0.20% of Nj State Employees Deferred Compensation Plan’s portfolio.

Other Hedge Funds, Including , Harel Insurance Investments Financial Services Ltd. added ALXN to its portfolio by purchasing 69 company shares during the most recent quarter which is valued at $9,499.Investors Capital Advisory Services boosted its stake in ALXN in the latest quarter, The investment management firm added 14 additional shares and now holds a total of 1,996 shares of Alexion Pharmaceuticals which is valued at $274,769. Alexion Pharmaceuticals makes up approx 0.05% of Investors Capital Advisory Services’s portfolio.Bbva Compass Bancshares Inc reduced its stake in ALXN by selling 544 shares or 18.38% in the most recent quarter. The Hedge Fund company now holds 2,415 shares of ALXN which is valued at $310,569. Alexion Pharmaceuticals makes up approx 0.02% of Bbva Compass Bancshares Inc’s portfolio.Huntington National Bank reduced its stake in ALXN by selling 282 shares or 50.36% in the most recent quarter. The Hedge Fund company now holds 278 shares of ALXN which is valued at $36,079.Exxonmobil Investment Management Inc Tx boosted its stake in ALXN in the latest quarter, The investment management firm added 3,135 additional shares and now holds a total of 57,988 shares of Alexion Pharmaceuticals which is valued at $7,214,867. Alexion Pharmaceuticals makes up approx 0.15% of Exxonmobil Investment Management Inc Tx’s portfolio.

Alexion Pharmaceuticals closed down -1.03 points or -0.75% at $136.08 with 11,71,458 shares getting traded on Monday. Post opening the session at $137.14, the shares hit an intraday low of $135.69 and an intraday high of $138.05 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Alexion Pharmaceuticals reported $1.13 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus of $1.17. The company had revenue of $753.10 million for the quarter, compared to analysts expectations of $743.05 million. The company’s revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.44 EPS.

Many Wall Street Analysts have commented on Alexion Pharmaceuticals. Shares were Reiterated by Stifel on Jul 29, 2016 to “Buy” and Lowered the Price Target to $ 182 from a previous price target of $195 .Shares were Reiterated by Barclays on Jul 29, 2016 to “Equal Weight” and Lowered the Price Target to $ 150 from a previous price target of $165 .RBC Capital Mkts Initiated Alexion Pharmaceuticals on Jul 13, 2016 to “Outperform”, Price Target of the shares are set at $188.

Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *